NYSEARCA:IHE iShares U.S. Pharmaceuticals ETF (IHE) Price, Holdings, & News $102.38 +0.39 (+0.38%) As of 07/24/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock About iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IHE alerts:Sign Up Key Stats Today's Range$102.00▼$102.9150-Day Range$87.45▼$103.4252-Week Range$64.94▼$103.70Volume164,337 shsAverage Volume141,047 shsMarket Capitalization$1.46 billionAssets Under Management$1.60 billionDividend Yield1.43%Net Expense Ratio0.39%Aggregate RatingModerate Buy ETF Overview iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors. Read More iShares U.S. Pharmaceuticals ETF ExpensesTypeIHEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.39%0.56%0.57%0.51%0.53%Other Expenses0.00%0.47%0.55%0.58%0.55%Total Expense0.39%0.74%0.76%0.74%0.73%Fee Waiver0.00%-0.71%-0.64%-0.70%-0.62%Net Expense0.39%0.59%0.63%0.58%0.60% Receive IHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares U.S. Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IHE ETF News HeadlinesiShares U.S. Pharmaceuticals ETFJuly 23 at 6:13 AM | markets.businessinsider.comIHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?July 19, 2026 | fool.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?July 18, 2026 | fool.comWhich Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH?July 16, 2026 | finance.yahoo.comIHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy?July 10, 2026 | fool.comSee More Headlines IHE ETF - Frequently Asked Questions How have IHE shares performed this year? iShares U.S. Pharmaceuticals ETF's stock was trading at $84.83 at the start of the year. Since then, IHE shares have increased by 20.7% and is now trading at $102.38. When did iShares U.S. Pharmaceuticals ETF's stock split? iShares U.S. Pharmaceuticals ETF shares split on the morning of Thursday, March 7th 2024.The 3-1 split was announced on Thursday, March 7th 2024. The newly minted shares were payable to shareholders after the market closes on Thursday, March 7th 2024. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Who are iShares U.S. Pharmaceuticals ETF's major shareholders? Top institutional investors of iShares U.S. Pharmaceuticals ETF include Insight Wealth Strategies LLC (1.07%), Avior Wealth Management LLC (0.04%), Focus Financial Network Inc. (0.02%) and CX Institutional. How do I buy shares of iShares U.S. Pharmaceuticals ETF? Shares of IHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iShares U.S. Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares U.S. Pharmaceuticals ETF investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), Visa (V), Adobe (ADBE), Lam Research (LRCX) and Advanced Micro Devices (AMD). Fund Details IssueriShares Fund NameiShares U.S. Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:IHE Inception Date5/1/2006 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason Webwww.iShares.com PhoneN/AFund Focus Asset ClassEquity BenchmarkDow Jones U.S. Select Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings60 Fund Statistics Assets Under Management$1.60 billion Average Daily Volume$377.99 thousand Discount/Premium-0.03% Administrator, Advisor and Custodian AdministratorCitibank, N.A. AdvisorBlackRock Fund Advisors CustodianCitibank, N.A. DistributorBlackRock Investments, LLC Transfer AgentCitibank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableN/A Short Interest266,083 shs Miscellaneous Outstanding Shares14,250,000Beta0.49 Creation Unit50,000 Creation Fee$306.00 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report Top 10 IHE HoldingsJohnson & Johnson (NYSE:JNJ)Holding Weight: 21.94%Eli Lilly and Company (NYSE:LLY)Holding Weight: 21.45%Bristol Myers Squibb (NYSE:BMY)Holding Weight: 4.52%Viatris (NASDAQ:VTRS)Holding Weight: 4.51%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 4.43%Royalty Pharma (NASDAQ:RPRX)Holding Weight: 4.41%Pfizer (NYSE:PFE)Holding Weight: 4.05%Zoetis (NYSE:ZTS)Holding Weight: 3.89%Jazz Pharmaceuticals (NASDAQ:JAZZ)Holding Weight: 3.48%Elanco Animal Health (NYSE:ELAN)Holding Weight: 2.89%Full Holdings DetailsIHE Sector ExposureIHE Industry Exposure This page (NYSEARCA:IHE) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe Weekly Options Trick Wall Street Doesn't AdvertiseThe most profitable trading desks don't guess market direction, they collect income regardless of it. A 25-yea...Base Camp Trading | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares U.S. Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares U.S. Pharmaceuticals ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
